Bionano Genomics Inc logo

BNGOU - Bionano Genomics Inc News Story

$7.55 0.2  2.4%

Sector
Healthcare
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6846

Bionano Genomics Announces Record Number of Presentations on Optical Genome Mapping and Structural Variation at the 2021 Annual Clinical Genetics Meeting of the ACMG

Mon 12th April, 2021 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210412:nGNX4QzYvj&default-theme=true


SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq:
BNGO) today announced it largest presence to date at the 2021 Annual Clinical
Genetics Meeting of the American College of Medical Genetics and Genomics
(ACMG), which is being held in a virtual format from April 13-16, 2021. The
meeting features a total of sixteen presentations by Saphyr customers and
Bionano scientists, almost three times the number presented last year and
nearly all based on work done in the United States.

“ACMG this year has the greatest number of presentations featuring Bionano
data to date,” commented Erik Holmlin, PhD, CEO of Bionano Genomics. “We
believe this multitude of presentations shows how significant Bionano’s
presence and that of optical genome mapping (OGM) has become in the medical
genetics community. The progress we are seeing here from the US market, where
almost all the data being presented at ACMG comes from, is particularly
encouraging since the US has a higher barrier to adoption that could be
addressed with data outlining the value proposition of our products and
technology. We are thrilled to share this important clinical data in all four
main target segments (prenatal, postnatal/constitutional genetics, blood
cancers and solid tumor analysis) at the meeting.”

Blood Cancers Oral and Poster Presentations:
* Platform Presentation, Thursday, April 15, 2021, 5:30 pm. OP340
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=11186&CONF=AM21&ssoOverride=OFF&CKEY=)
– Optical Genome Mapping for Assessment of Genomic Aberrations in Acute
Myeloid Leukemia: A Multicenter Evaluation 


* eP085
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=11277&CONF=AM21&ssoOverride=OFF&CKEY=)
– Efficient workflow for detection of clinically relevant abnormalities in
leukemias according to NCCN guidelines


* eP068
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=10823&CONF=AM21&ssoOverride=OFF&CKEY=)
– Optical Genome Mapping Detects Rare Genetic Drivers in Pediatric
B-Lymphoblastic Leukemia
Prenatal Oral and Poster Presentations:
* Product Theater (available on demand): Next-Generation Cytogenomic
Characterization of Prenatal Cases by Optical Genome Mapping


* eP501
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=11135&CONF=AM21&ssoOverride=OFF&CKEY=)
– Generation of a Prenatal Workflow for Identification of Structural
Variation by Optical Genome Mapping (OGM) 


* eP502
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=11205&CONF=AM21&ssoOverride=OFF&CKEY=)
– Next-Generation Cytogenomic Characterization of Prenatal Cases by Optical
Genome Mapping
Post-Natal Oral and Poster Presentations:
* Platform Presentation, Wednesday, 4/14, 4:15 pm, part of Scientific
Concurrent Session “Hot Topics: Pushing the Boundaries of Genome
Sequencing” – Clinically Relevant Genes Hiding In Plain Sight And How Long
Range Technologies Resolve Them


* eP436
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=11181&CONF=AM21&ssoOverride=OFF&CKEY=)
– Identification of Structural Variation in Constitutional Disorders by
Optical Genome Mapping


* eP406
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=11015&CONF=AM21&ssoOverride=OFF&CKEY=)
– Optical Genome Mapping Enables Constitutional Chromosomal Aberration
Detection: Proof-of-Principle Study with 85 Samples


* eP294
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=11204&CONF=AM21&ssoOverride=OFF&CKEY=)
– High Throughput Analysis of Disease Repeat Expansions and Contractions by
Optical Mapping


* eP447
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=11239&CONF=AM21&ssoOverride=OFF&CKEY=)
– Improving and Accelerating Clinical Molecular Diagnosis of Severe
Hemophilia A with Optical Genome Mapping Technology


* eP370
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=10737&CONF=AM21&ssoOverride=OFF&CKEY=)
– Fascioscapulohumeral Muscular Dystrophy Genetic Testing by Optic Mapping
Solid Tumors Poster Presentations:
* eP083
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=11213&CONF=AM21&ssoOverride=OFF&CKEY=)
– Clinical Utility of Optical Genome Mapping (OGM) in Cytogenetic Analysis
of Brain Tumors


* eP388
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=10899&CONF=AM21&ssoOverride=OFF&CKEY=)
– Optical Genomic Mapping Reveals Balanced and Unbalanced Cytogenetic
Findings Associated with Tumor-forming Potential in a Prostate Cancer Cell
line (M2205)
Other Bionano Poster Presentations:
* eP407
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=11028&CONF=AM21&ssoOverride=OFF&CKEY=)
– NeuroSCORE: A Genome-wide OMICs Based Model to Identify Disease Associated
Genes of the Central Nervous System


* eP365
(https://acmg.planion.com/Web.User/AbstractDet?ACCOUNT=ACMG&ABSID=10727&CONF=AM21&ssoOverride=OFF&CKEY=)
– PRKX/PRKY-Mediated Xp;Yp Translocations: A Significant Contributor to
SRY-Positive 46,XX TDSD and Potential Risk of Recurrence in Common Yp
Inversion Carriers
More details can be found
at https://www.acmgmeeting.net/acmg2021/Public/mainhall.aspx

About the ACMG Meeting

The ACMG Meeting is the genetics meeting most focused specifically on the
practical applications of genetic discoveries to clinical medicine. Topics
range from common conditions to rare diseases. The ACMG Annual Meeting
attracts medical and scientific leaders from around the world who are working
to apply research in genetics and the human genome to the diagnosis,
management, treatment and prevention of genetic conditions and rare and common
diseases in patients in the clinical setting.

About Bionano Genomics

Bionano is a genome analysis company providing tools and services based on its
Saphyr system to scientists and clinicians conducting genetic research and
patient testing, and providing diagnostic testing for those with autism
spectrum disorder (ASD) and other neurodevelopmental disabilities through its
Lineagen business. Bionano’s Saphyr system is a research use only platform
for ultra-sensitive and ultra-specific structural variation detection that
enables researchers and clinicians to accelerate the search for new
diagnostics and therapeutic targets and to streamline the study of changes in
chromosomes, which is known as cytogenetics. The Saphyr system is comprised of
an instrument, chip consumables, reagents and a suite of data analysis tools.
Bionano provides genome analysis services to provide access to data generated
by the Saphyr system for researchers who prefer not to adopt the Saphyr system
in their labs. Lineagen has been providing genetic testing services to
families and their healthcare providers for over nine years and has performed
over 65,000 tests for those with neurodevelopmental concerns. For more
information, visit www.bionanogenomics.com or www.lineagen.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Words such as “may,”
“will,” “expect,” “plan,” “anticipate,” “estimate,”
“intend” and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these forward-looking
statements. Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the timing and content of the presentations
identified in this press release; our presence in the medical genetics
community; our ability to address barriers to adoption in the United States;
and the execution of Bionano’s strategy, including with respect to our
target growth markets. Each of these forward-looking statements involves risks
and uncertainties. Actual results or developments may differ materially from
those projected or implied in these forward-looking statements. Factors that
may cause such a difference include the risks and uncertainties associated
with: Indalo Bio’s ability to successfully develop assays on the Saphyr
system and/or make its technology widely available in Africa; the impact of
the COVID-19 pandemic on our business and the global economy; general market
conditions; changes in the competitive landscape and the introduction of
competitive products; changes in our strategic and commercial plans; our
ability to obtain sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research institutions to
obtain funding to support adoption or continued use of our technologies; the
loss of key members of management and our commercial team; and the risks and
uncertainties associated with our business and financial condition in
general, including the risks and uncertainties described in our filings with
the Securities and Exchange Commission, including, without limitation, our
Annual Report on Form 10-K for the year ended December 31, 2020 and in other
filings subsequently made by us with the Securities and Exchange Commission.
All forward-looking statements contained in this press release speak only as
of the date on which they were made and are based on management's assumptions
and estimates as of such date. We do not undertake any obligation to publicly
update any forward-looking statements, whether as a result of the receipt of
new information, the occurrence of future events or otherwise.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations and 
Media Contact:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com



(https://www.globenewswire.com/NewsRoom/AttachmentNg/3253163c-a161-4291-875a-c40a9683c9f8)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.